145 related articles for article (PubMed ID: 12112073)
1. Evolution of the response to levodopa during the first 4 years of therapy.
Nutt JG; Carter JH; Lea ES; Sexton GJ
Ann Neurol; 2002 Jun; 51(6):686-93. PubMed ID: 12112073
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-duration responses to levodopa during the first year of levodopa therapy.
Nutt JG; Carter JH; Van Houten L; Woodward WR
Ann Neurol; 1997 Sep; 42(3):349-55. PubMed ID: 9307256
[TBL] [Abstract][Full Text] [Related]
3. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.
McColl CD; Reardon KA; Shiff M; Kempster PA
Mov Disord; 2002 Nov; 17(6):1227-34. PubMed ID: 12465061
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of levodopa.
Nutt JG
Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
[TBL] [Abstract][Full Text] [Related]
5. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal study of the motor response to levodopa in Parkinson's disease.
Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal study of the levodopa motor response in Parkinson's disease: relationship between cognitive decline and motor function.
Alty JE; Clissold BG; McColl CD; Reardon KA; Shiff M; Kempster PA
Mov Disord; 2009 Dec; 24(16):2337-43. PubMed ID: 19890972
[TBL] [Abstract][Full Text] [Related]
8. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
Mouradian MM; Juncos JL; Fabbrini G; Schlegel J; Bartko JJ; Chase TN
Ann Neurol; 1988 Sep; 24(3):372-8. PubMed ID: 3228271
[TBL] [Abstract][Full Text] [Related]
9. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
Mouradian MM; Heuser IJ; Baronti F; Chase TN
Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
[TBL] [Abstract][Full Text] [Related]
10. Central levodopa influx and the clinical motor response to levodopa in patients with Parkinson disease complicated with motor fluctuations and dyskinesias.
López-Ariztegui N; Arévalo MA; de Ceballos ML; Grandas F
Clin Neuropharmacol; 2009; 32(6):321-5. PubMed ID: 19667975
[TBL] [Abstract][Full Text] [Related]
11. Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.
Zappia M; Colao R; Montesanti R; Rizzo M; Aguglia U; Gambardella A; Oliveri RL; Quattrone A
Ann Neurol; 1997 Aug; 42(2):245-8. PubMed ID: 9266736
[TBL] [Abstract][Full Text] [Related]
12. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
Hauser RA; McDermott MP; Messing S
Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
[TBL] [Abstract][Full Text] [Related]
14. When do levodopa motor fluctuations first appear in Parkinson's disease?
Stocchi F; Jenner P; Obeso JA
Eur Neurol; 2010; 63(5):257-66. PubMed ID: 20332641
[TBL] [Abstract][Full Text] [Related]
15. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
[TBL] [Abstract][Full Text] [Related]
16. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
17. The response to levodopa in Parkinson's disease: imposing pharmacological law and order.
Nutt JG; Holford NH
Ann Neurol; 1996 May; 39(5):561-73. PubMed ID: 8619540
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
19. [Motor fluctuations and dyskinesias in Parkinson's disease: variables that discriminate both complications in a sample of 285 patients].
Gómez JC; Rouco I; Velasco F; Tijero B; Garamendi I; Lezcano E; Zarranz JJ
Neurologia; 2008 Oct; 23(8):494-8. PubMed ID: 18770057
[TBL] [Abstract][Full Text] [Related]
20. Levodopa induced motor complications in Thai Parkinson's disease patients.
Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
